Association of MASLD with the risk of extrahepatic cancers: A systematic review and meta‐analysis of 18 cohort studies
European Journal of Clinical Investigation · 2024-11 · 54 (11)
DOI: 10.1111/eci.14276 ↗Kurz gefasst
Metaanalyse in der Zeitschrift European Journal of Clinical Investigation, online erschienen am 28.06.2024. Verfasst von Ben-Gang Zhou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dalian Medical University, Dalian, Liaoning Province, China. Hauptthemen laut MEDLINE: Neoplasms, Stomach Neoplasms. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Background
Numerous recent studies have explored the association between metabolic dysfunction‐associated steatotic liver disease (MASLD) and the risk of various extrahepatic cancers. However, the conclusions were inconclusive. The aim of this study was to clarify this relationship by conducting a robust meta‐analysis.
Methods
Systematic searches were conducted on PubMed, Embase and Web of Science databases to identify relevant cohort studies published prior to February 2024. Hazard ratios (HRs) and their corresponding 95% confidence intervals (95% CIs) were combined using a random‐effects model in this meta‐analysis.
Results
Eighteen cohort studies (approximately 16.7 million participants) were finally included in this meta‐analysis. MASLD was linked to a higher risk of extrahepatic cancers, such as gastric ( n = 10, HR = 1.47, 95% CI: 1.07–2.01), colorectal ( n = 13, HR = 1.33, 95% CI: 1.16–1.53), pancreatic ( n = 8, HR = 1.41, 95% CI: 1.11–1.79), biliary tract ( n = 5, HR = 1.27, 95% CI: 1.18–1.37), thyroid ( n = 6, HR = 1.46, 95% CI: 1.02–2.09), urinary system ( n = 10, HR = 1.45, 95% CI: 1.25–1.69), breast ( n = 11, HR = 1.17, 95% CI: 1.08–1.26) and female genital organ cancers ( n = 10, HR = 1.36, 95% CI: 1.11–1.66). However, there was no statistically significant association between MASLD and the risk of head and neck ( n = 6, HR = 1.03, 95% CI: 99–1.07), oesophageal ( n = 9, HR = 1.26, 95% CI: 0.86–1.86), lung ( n = 9, HR = 1.01, 95% CI: 0.92–1.10), prostate ( n = 9, HR = 1.06, 95% CI: 0.94–1.19) or small intestine cancer ( n = 2, HR = 1.75, 95% CI: 1.00–3.06).
Conclusions
This latest large‐scale meta‐analysis indicated that MASLD was associated with an increased risk of various extrahepatic cancers, such as gastric, colorectal, pancreatic, biliary duct, thyroid, urinary system, breast, skin and female genital cancers. Further research is needed to investigate the mechanisms underlying these associations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dalian Medical University, Dalian, Liaoning Province, China.
- Department of Gastroenterology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu Province, China.
ORCID-Profile: Ben-Gang Zhou
Zitieren
APA
Zhou, B. G., Jiang, X., She, Q., & Ding, Y. B. (2024). Association of MASLD with the risk of extrahepatic cancers: A systematic review and meta‐analysis of 18 cohort studies. European Journal of Clinical Investigation, 54(11). https://doi.org/10.1111/eci.14276
Vancouver
Zhou BG, Jiang X, She Q, Ding YB. Association of MASLD with the risk of extrahepatic cancers: A systematic review and meta‐analysis of 18 cohort studies. European Journal of Clinical Investigation. 2024;54(11). doi:10.1111/eci.14276
BibTeX
@article{Zhou2024,
author = {Zhou, Ben-Gang and Jiang, Xin and She, Qiang and Ding, Yan-Bing},
title = {Association of MASLD with the risk of extrahepatic cancers: A systematic review and meta‐analysis of 18 cohort studies},
journal = {European Journal of Clinical Investigation},
year = {2024},
volume = {54},
number = {11},
doi = {10.1111/eci.14276}
}
EUVIMED